ClinicalTrials.gg
RecruitingNCT05811780Updated Apr 13, 2023

The University of Freiburg Medical Center Extracorporeal Organ Support Device Registry

An observational study in Medical Condition Requiring Extracorporeal Organ Support, sponsored by University Hospital Freiburg. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2023-04-13.

Sponsored by University Hospital Freiburg · Observational

How we know

From the registry’s dates

  • Started Apr 2014; still recruiting 12 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Respiratory Distress Syndrome with a site in Germany — 7 open to participants now, 8 under way, 1 of them phase 3. Respiratory Distress Syndrome · Germany.

Planned enrollment
5th of 21
1,500 · median 132
Started
2014
with 4 others
Observational
22 of 48
2 open now
Registered
46th of 48
by date
Lead sponsor
2 of 48
University Hospital Freiburg

Among the 48 studies in Respiratory Distress Syndrome with a site in Germany, this one is the 5th largest by planned enrollment of the 21 observational ones that give a count, is one of 5 that started in 2014, is one of 22 observational ones, and was the 46th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

7 of the 48 studies in Respiratory Distress Syndrome with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Respiratory Distress Syndrome with a site in Germany, or all of them as a file.
02

Study summary

A prospective registry collecting pseudonymized clinical and treatment data from all patients treated with extracorporeal organ support (i.e., VV ECMO, VA ECMO, ECPR, Impella, IABP, and others) on the wards of the Department of Interdisciplinary Medical Intensive Care at the Freiburg University Medical Center.

03

Conditions studied

  • Medical Condition Requiring Extracorporeal Organ Support

Keywords

  • Acute Respiratory Distress Syndrome
  • acute respiratory failure
  • severe respiratory failure
  • cardiogenic shock
  • cardiac arrest
  • extracorporeal cardiopulmonary resuscitation
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients receiving extracorporeal organ support and being treated in the Department of Interdisciplinary Medical Intensive Care of the Freiburg University Medical Center

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Treatment with any kind of extracorporeal organ support

Exclusion criteria

Exclusion Criteria:

  • none
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Hospital survival

    Survival of index hospitalization (yes/no)

    Time frame: 30 days

Other outcomes

  1. Mesenteric ischemia

    Occurrence of mesenteric ischemia

    Time frame: 30 days

  2. Fluid balance

    Patient fluid balance (difference between fluid input and output)

    Time frame: 7 days

  3. ECMO run-time

    Duration of ECMO support

    Time frame: 60 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2014 (actual). Primary completion is estimated for Dec 2030, 200 months after the start.

Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 200 months is above that.

Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2023
First posted
Apr 13, 2023
StartActual
Apr 29, 2014
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2035
Last update
Apr 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05811780
Lead sponsor
University Hospital Freiburg
Responsible party
PD Dr. Alexander Supady (Co-Principal Investigator, University Hospital Freiburg) — Principal investigator
First posted
Apr 13, 2023
Start date
Apr 29, 2014
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Apr 13, 2023

Study contacts

Tobias Wengenmayer, Prof. Dr.
Contact
tobias.wengenmayer@uniklinik-freiburg.de
+49761270 ext. 35910
Alexander Supady, PD Dr.
Contact
alexander.supady@uniklinik-freiburg.de
+49761270 ext. 73790
Tobias Wengenmayer, Prof. Dr.
study director · University of Freiburg
Dawid L Staudacher, PD Dr.
principal investigator · University of Freiburg
Paul M Biever, Dr.
principal investigator · University of Freiburg
Jonathan Rilinger, PD Dr.
principal investigator · University of Freiburg
Alexander Supady, PD Dr.
principal investigator · University of Freiburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion